Drilldown/Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Benzodiazepine

or Empathogen

or [[:Category:Insulins|Insulin]]

Use the filters below to narrow your results.

None (2) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) · '"`UNIQ--vote-00000584-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Ultra-rapid formulations (Lyumjev) add treprostinil and citrate to accelerate absorption further'"`UNIQ--ref-00000585-QINU`"'. (1) · '"`UNIQ--vote-00001356-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio'"`UNIQ--ref-00001357-QINU`"'. (1)

None (38) · 0.25 mg (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM (1) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)

None (38) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) · 100 U/mL (Humalog, Admelog, Lyumjev) vials, pens, cartridges; 200 U/mL Humalog KwikPen (1) · 100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) · 100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1) · 100 U/mL FlexTouch pen, vial (1)

None (38) · 10 mg/d (1) · Titrated to glucose (1) · Titrated to glucose; no fixed ceiling (2) · Titrated to glucose; no fixed maximum (2)

None (38) · insulin pumps (2) · IV (1) · IV (continuous infusion for DKA) (1) · Oral (1) · Subcutaneous (3) · Subcutaneous (never IV; not for use in insulin pumps) (2)

None (38) · 1-2 hours (2) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1) · SC: 5-15 minutes; ultra-rapid Lyumjev faster (1) · ~1 hour (1)

None (38) · 3-5 hours (2) · 6 h (immediate-release); ~11 h (extended-release) (1) · >42 hours per dose (effectively flat once at steady state) (1) · ~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1) · ~24 hours per dose (peakless profile by design) (1)

None (38) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~1 hour SC'"`UNIQ--ref-00000589-QINU`"' (1) · ~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) · ~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) · ~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1) · ~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"' (1)

None (38) · 80-90% oral (1) · ~100% from subcutaneous depot (3) · ~100% from subcutaneous depot (by definition of the route) (1) · ~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)

None (38) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; lispro is widely used.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · One of the better-studied basal insulin analogs in pregnancy; reassuring data.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

None (38) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (4) · [[USLegal:Prescription only|Rx-only]] in US (some OTC formulations exist) (1)